Safety profile of proton pump inhibitors according to the spontaneous reports of suspected adverse reactions

2006 ◽  
Vol 44 (11) ◽  
pp. 548-556 ◽  
Author(s):  
E. Salgueiro ◽  
T. Rubio ◽  
A. Hidalgo ◽  
G. Manso
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Safety Profile ◽  
Adverse Reactions ◽  
Spontaneous Reports ◽  
Suspected Adverse Reactions

Adverse reactions related to proton pump inhibitors in pediatric population: an analysis of spontaneous reporting data

2021 ◽  
Author(s):  
Valeria Dipasquale ◽  
Giuseppe Cicala ◽  
Francesca Laganà ◽  
Paola Cutroneo ◽  
Patrizia Felicetti ◽  
...  
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Adverse Reactions ◽  
Spontaneous Reporting ◽  
Pediatric Population ◽  
Reporting Data

Proton pump inhibitors in the light of clinical studies and safety profile of long term use

2018 ◽  
Vol 72 (5) ◽  
pp. 432-440
Author(s):  
Martin Ďuriček ◽  
Peter Bánovčin ◽  
Rudolf Hyrdel
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Safety Profile ◽  
Clinical Studies

scholarly journals Interactions between Natural Health Products and Oral Anticoagulants: Spontaneous Reports in the Italian Surveillance System of Natural Health Products

2011 ◽  
Vol 2011 ◽  
pp. 1-5 ◽  
Author(s):  
Angelica Paoletti ◽  
Eugenia Gallo ◽  
Silvia Benemei ◽  
Michele Vietri ◽  
Francesco Lapi ◽  
...  
Keyword(s):  
Natural Products ◽  
Adverse Reactions ◽  
Vitamin K Antagonists ◽  
Oral Anticoagulants ◽  
Natural Health Products ◽  
Natural Health ◽  
Herbal Products ◽  
Spontaneous Reports ◽  
Health Products ◽  
Suspected Adverse Reactions

Introduction. The safety of vitamin K antagonists (VKA) use can be compromised by many popular herbal supplements taken by individuals. The literature reports that 30% of warfarin-treated patients self-medicates with herbs. Possible interactions represent an health risk. We aimed to identify all herbs-oral anticoagulants interactions collected in the Italian database of suspected adverse reactions to “natural health” products.Methods. The Italian database of spontaneous reports of suspected adverse reactions to natural products was analyzed to address herb-VKAs interactions.Results. From 2002 to 2009, we identified 12 reports with 7 cases of INR reduction in patients treated with warfarin (n=3) and acenocoumarol (n=4), and 5 cases of INR increase (all warfarin associated). It was reported 8 different herbal products as possibly interacting.Discussion. Our study confirms the risk of interactions, highlighting the difficulty to characterize them and their mechanisms and, finally, prevent their onset. The reported data underline the urgent need of healthcare providers being aware of the possible interaction between natural products and VKA, also because of the critical clinical conditions affecting patients. This is the first step to have the best approach to understand possible INR alterations linked to herb-VKA interaction and to rightly educate patients in treatment with VKA.

scholarly journals Proton Pump Inhibitor use in Hospitalized Patients: Is Overutilization Becoming a Problem?

2012 ◽  
Vol 5 ◽  
pp. CGast.S9588 ◽  
Author(s):  
Cheryl Durand ◽  
Kristine C. Willett ◽  
Alicia R. Desilets
Keyword(s):  
Clostridium Difficile ◽  
Proton Pump Inhibitor ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Clostridium Difficile Infection ◽  
Adverse Reactions ◽  
Recent Literature ◽  
Hospitalized Patients ◽  
Increased Risk ◽  
Appropriate Therapy

Proton pump inhibitors (PPIs) are among the most common classes of medications prescribed. Though they were previously thought of as safe, recent literature has shown risks associated with their use including increased risk for Clostridium difficile infection, pneumonia, and fractures. Due to these risks, it is important to determine if PPIs are being used appropriately. This review evaluates seven studies in hospitalized patients. Additionally, this review evaluates literature pertaining to recently discovered adverse reactions; all studies found PPIs are being overutilized. Findings highlight the importance of evaluating appropriate therapy with these agents and recommending discontinuation if a proper indication does not exist.

Proton Pump Inhibitors and the Risk of Community-Acquired Pneumonia: An Updated Meta-analysis

2021 ◽  
pp. 106002802110392
Author(s):  
Xuejiao Xun ◽  
Qifan Yin ◽  
Yuhao Fu ◽  
Xueru He ◽  
Zhanjun Dong
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Literature Search ◽  
Primary Outcome ◽  
Adverse Reactions ◽  
Meta Analysis ◽  
Community Acquired Pneumonia ◽  
Published Evidence ◽  
Increased Risk ◽  
Comprehensive Literature Search

Background: Some studies suggested an increased risk of community-acquired pneumonia (CAP) among proton pump inhibitors (PPI) users. However, the published evidence is inadequate to define the association between PPI use and the risk of CAP. Objective: The aims of our meta-analysis were to systematically assess the association between the risk of CAP and PPI use in adults to reduce the adverse effects of PPI and ensure the safety of medication for patients. Methods: A comprehensive literature search was conducted, published between January 1, 2004, and February 1, 2021. The primary outcome was the incidence of CAP. This meta-analysis was performed using odds ratios (ORs) with 95% CIs as effective measures; 13 studies including 2 098 804 patients were enrolled in our meta-analysis. Results: Our study revealed that the incidence of CAP was higher in PPI users than non -PPI users [OR = 1.37 (95% CI = 1.22–1.53)], especially for PPI duration < 30 days [OR = 1.49 (95% CI = 1.34–1.66)]. Compared with non-PPI use, PPI use increased the incidence of CAP in the stroke disease population [OR = 1.52 (95% CI = 1.33–1.75)], but not in the liver disease population [OR = 1.13 (95% CI = 0.98–1.30)]. Conclusions and Relevance: Using PPI could increase the risk of CAP when compared to not using PPI. PPI use increased the incidence of CAP in patients with stroke. Clinicians and clinical pharmacists should weigh the benefits before medication and strictly control the indication of the prescription, so as to reduce adverse reactions.

scholarly journals QUALIMETRIC ANALYSIS OF PROTON PUMP INHIBITORS IN UKRAINE

2019 ◽  
Vol 72 (9) ◽  
pp. 1769-1773
Author(s):  
Olha V. Makarenko ◽  
Malika M. Karimova ◽  
Alona M. Masheiko ◽  
Nataliia M. Onul
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Safety Profile ◽  
Axiomatic Approach ◽  
Dosage Forms ◽  
Pharmaceutical Market ◽  
Quality Indices ◽  
Qualitative Properties ◽  
Quality Properties ◽  
The Subject

Introduction: On the pharmaceutical market of Ukraine, there are six international non-proprietary names of proton pump inhibitors (PPIs) – Omeprazole, Pantoprazole, Lansoprazole, Rabeprazole, Esomeprazole, Dexlansoprazole, which differ in a number of pharmacokinetic and pharmacodynamic parameters, safety profile, range of dosage forms and their cost. The aim: To investigate the competitiveness of proton pump inhibitors registered in Ukraine by comparing the parameters of their quality properties using the method of qualimetric analysis. Materials and methods: Qualimetric analysis is based on the deductive-axiomatic approach, which allows quantifying the qualitative properties of drugs and determining the degree of competitiveness of each of them in the pharmaceutical market of Ukraine. The qualitative properties of PPIs in terms of consumer are efficacy, safety, convenience of use and cost. The subject of the study was 133 trademarks of PPIs registered in Ukraine. Results: The highest qualimetric values were obtained by omeprazole (Kk = 0.73) and its S-isomer esomeprazole (Kk = 0.66). Pantoprazole was inferior to them to a certain extent (Kk = 0.64). Lansoprazole (Kk = 0.53), rabeprazole (Kk = 0.50) and dexlansoprazole (Kk = 0.44) had the lowest values of the quality indices. Conclusions: According to the results of the study of the PPIs’ competitiveness for parameters characterizing efficacy, safety, convenience of use and cost, assessed by qualimetric analysis, it has been established that the most completely and qualitatively satisfying consumer’s needs are omeprazole and its S-isomer, esomeprazole.

Sign in / Sign up

Export Citation Format

Share Document